A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients with Erectile Dysfunction
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Simmerafil (Primary)
- Indications Erectile dysfunction
- Focus Adverse reactions; Registrational
- Sponsors Vigonvita Life Sciences
- 24 Oct 2024 Planned number of patients changed from 400 to 472.
- 25 Apr 2024 Status changed from not yet recruiting to recruiting.
- 12 Mar 2024 New trial record